Navigation Links
Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
Date:12/14/2010

CAMBRIDGE, Mass., Dec. 14, 2010 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.  

The Phase 1 trial will evaluate ascending single doses of TRX518 in patients with malignant melanoma. The clinical trial will be conducted by leading cancer researchers at the Memorial Sloan-Kettering Cancer Center and is supported by research funding to Tolerx from the Cancer Research Institute and clinical trials management expertise from the Ludwig Institute for Cancer Research Ltd., through its Cancer Vaccine Acceleration Fund (CVAF).

"We are very enthusiastic about leading the clinical study of TRX518 and evaluating this innovative immunotherapy, which offers a new approach to help cancer patients," said Jedd Wolchok, MD, PhD, director of immunotherapy clinical trials at Memorial Sloan-Kettering Cancer Center.  "In collaboration with Tolerx and the leadership team at the CVAF, we have assisted with the unique aspects of immunotherapy trials in cancer, including patient enrollment criteria, dosing strategy, trial endpoints, and other considerations to ensure the highest standards and quality results for the TRX518 Phase 1 study."

This open label, non-randomized, ascending dose design will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending intravenous doses of TRX518 in up to 40 patients with advanced stage III and IV malignant melanoma.  The goal is to determine the maximum tolerated dose of TRX518 as patients are assessed over the 18-week core study period.  In future clinical programs, Tolerx plans to evaluate TRX518 f
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
2. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
3. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
4. Laureate Announces Manufacturing Agreement with Tolerx
5. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
6. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
7. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
8. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
9. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Patients who were treated with a statin ... were significantly more likely to survive than those who ... JAMA Neurology . This study was conducted by ... of cholesterol-lowering statins can improve survival in victims of ... or obstruction of a blood vessel that blocks blood ...
(Date:9/22/2014)... researchers at the USC Viterbi School of Engineering, ... microfluidic system quickly and cheaply by simply snapping ... systems are used in many fields including engineering, ... of fluids for use in applications such as ... testing, and synthetic chemistry. Traditionally, microfluidic devices are ...
(Date:9/22/2014)... Minnesota electrical engineering researchers have developed a unique ... mechanical transportation of light. The discovery could have ... optical devices for computation and communication. , The ... computer engineering assistant professor Mo Li and his ... and will appear in the October issue of ...
(Date:9/22/2014)... 22, 2014 US demand to rise 3.9% ... biocides is forecast to rise 3.9 percent per year ... is projected to increase 1.3 percent per year to ... rebound in construction expenditures will support demand for biocides ... while growth in consumer spending and manufacturing output will ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Engineers show light can play seesaw at the nanoscale 2US Biocides Market 2US Biocides Market 3
... and Webcast on November 9 at 8:00 a.m. ... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... matrix, today reported financial,results for the three and ... unique capabilities in navigating the complexities of the,extracellular ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today reported financial ... Net loss for the quarter and nine months ended ... per share and $0.46 per share,compared to a net loss ... share, in the same periods last year. Revenues were ...
... 8 Inverness Medical,Innovations, Inc. (Amex: IMA ), ... market and other conditions, 7,000,000 shares of its common,stock ... public offering. Certain selling stockholders of the Company,are also ... stock in the,offering. The Company expects to grant the ...
Cached Biology Technology:Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 2Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 3
(Date:9/23/2014)... Pattern formation is essential in the development of animals ... how can genetic information be translated in a reliable ... , The French-flag model of stripe formation is ... by the different colours of the French flag, is ... i.e. at high, middle or low concentrations of the ...
(Date:9/23/2014)... 23 de septiembre de 2014 ... 1290 Infinity II LC, el nuevo instrumento ... su portafolio de cromatografía líquida. El sistema ... de laboratorio que alcancen nuevos niveles de ... uso y capacidad de integración de laboratorio. ...
(Date:9/22/2014)... Researchers at the University of Chicago have shown that ... (ICU) only a handful of pathogenic microbe species remain ... pathogens and discovered that some can become deadly when ... to illness. , The findings, published in mBio ... for Microbiology, may lead to better monitoring and treatment ...
Breaking Biology News(10 mins):Recreating the stripe patterns found in animals by engineering synthetic gene networks 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3
... best-studied single-celled organisms around, is a master of industrial efficiency. ... just one product: itself. It exists to make copies of ... the lowest possible cost, with the greatest possible efficiency. ... by the energy and resources it uses to maintain its ...
... facial structure of an ancient relative of modern humans ... hard nuts and seeds as part of a survival ... team of researchers that includes Florida State University,s Dennis ... Proceedings of the National Academy of Science, ...
... gearing up to return to Russia to oversee preparations for ... launch on 16 March 2009. This follows implementation of the ... delayed the launch of GOCE by Eurockot Launch Services last ... at the Plesetsk Cosmodrome in northern Russia to arrange logistical ...
Cached Biology News:Bacteria are models of efficiency 2March launch planned for ESA's gravity mission 2
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
IHC Select Anti-p53, prediluted,wild & mutant, a.a. 19-26, clone DO-7 Immunogen: Human p53 Available Date: 37775...
Feline Rhinotracheitis Virus...
Biology Products: